1001906-63-3 Usage
General Description
1-(1H-Indazol-5-yl)ethanone is a chemical compound characterized by an indazole group, which is a type of nitrogenous heterocycle, and an ethanone or acetyl group. Its structure features a benzene ring fused to a nitrogen-containing pyrazole ring with an ethanone side chain attached to the fifth carbon atom. It is a less common compound and typically utilized in chemical research or industry for organic synthesis processes, mostly in the development of new pharmaceutical substances due to the useful pharmacophoric properties of the indazole nucleus. Details including its exact physical and chemical properties, stability, and safety measures may vary depending on a given source and should be verified accordingly.
Check Digit Verification of cas no
The CAS Registry Mumber 1001906-63-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,1,9,0 and 6 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1001906-63:
(9*1)+(8*0)+(7*0)+(6*1)+(5*9)+(4*0)+(3*6)+(2*6)+(1*3)=93
93 % 10 = 3
So 1001906-63-3 is a valid CAS Registry Number.
1001906-63-3Relevant articles and documents
Scaffold oriented synthesis. Part 4: Design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing heterocycle forming and multicomponent reactions
Akritopoulou-Zanze, Irini,Wakefield, Brian D.,Gasiecki, Alan,Kalvin, Douglas,Johnson, Eric F.,Kovar, Peter,Djuric, Stevan W.
, p. 1480 - 1483 (2011/04/23)
We report the synthesis and biological evaluation of 5-substituted indazoles as kinase inhibitors. The compounds were synthesized in a parallel synthesis fashion from readily available starting materials employing heterocycle forming and multicomponent reactions and were evaluated against a panel of kinase assays. Potent inhibitors were identified for Gsk3β, Rock2, and Egfr.
SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS
-
Page/Page column 42, (2008/06/13)
This invention provides a compound of the formula (I): And their use for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition compri
